C4 Therapeutics Inc (CCCC) is a company in the biotechnology sector that specializes in targeted protein degradation. The company's innovative approach involves the use of small molecules to selectively eliminate disease-causing proteins. C4 Therapeutics' unique platform has the potential to revolutionize the treatment of a wide range of diseases, including cancer and neurodegenerative disorders.

When it comes to technical analysis of C4 Therapeutics Inc (CCCC) stock, several indicators can provide valuable insights. One such indicator is the Relative Strength Index (RSI), which measures the speed and change of price movements. By analyzing the RSI, investors can determine whether a stock is overbought or oversold and make informed trading decisions.

C4 Therapeutics  (CCCC) Technical Analysis

Learn about C4 Therapeutics Inc (CCCC) stock technical analysis using various indicators like RSI, ADX, MACD. Analyze CCCC stock's performance, trends, and momentum. Make informed investment decisions. Find out more.

C4 Therapeutics Inc (CCCC) Technical Analysis - Stock Indicators, RSI, ADX, MACD

C4 Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops novel therapeutic candidates to degrade disease-causing proteins for the treatment of cancer, neurodegenerative conditions, and other diseases. Its lead product candidate is CFT7455, an orally bioavailable MonoDAC degrader of protein that is in Phase 1/2 trial targeting IKZF1 and IKZF3 for multiple myeloma and non-Hodgkin lymphomas, including peripheral T-cell lymphoma and mantle cell lymphoma. The company is also developing CFT8634, an orally bioavailable BiDAC degrader of BRD9, a protein target for synovial sarcoma and SMARCB1-deleted solid tumors; CFT1946, an orally bioavailable BiDAC degrader targeting V600X mutant BRAF to treat melanoma, non-small cell lung cancer (NSCLC), colorectal cancer, and other solid malignancies; CFT8919, an orally bioavailable, allosteric, and mutant-selective BiDAC degrader of epidermal growth factor receptor, or EGFR, with an L858R mutation in NSCLC; and earlier stage programs comprising RET degraders for the treatment of various cancers. C4 Therapeutics, Inc. has strategic collaborations with F. Hoffmann-La Roche Ltd and Hoffmann-La Roche Inc.; Biogen MA, Inc.; and Calico Life Sciences LLC. The company was incorporated in 2015 and is headquartered in Watertown, Massachusetts.

C4 Therapeutics 

NASDAQ

This suggests that the technical indicators do not strongly favor either a buying or selling stance. In such cases, investors may need to rely on additional fundamental or market analysis to make a well-informed decision.

Balanced or Uncertain

MACD

WILLR

STOCHRSI

Free

is to help users identify stocks that trade at a low value relative to their fundamentals. Suitable for value investors such as Warren Buffet.

Name	Value	Action	infoPnL (10y)
auto_graphRSI	48.45	Neutral	-18.5%
auto_graphMACD	-1.91	Neutral	-6.8%
auto_graphCCI	-18.53	Neutral	-49.2%
auto_graphADX	16.19	Neutral	-17.8%
auto_graphATR	7.42	Buy	-
auto_graphWILLR	-61.18	Neutral	-57.7%
auto_graphROC	-21.02	Neutral	-6.5%
auto_graphSTOCHRSI	100.00	Sell	14.4%

Buy	1	-87.50%
Hold	6	-25.00%
Sell	1	-87.50%

Trendlines, Support and Resistance

Welcome to Stocklytics

Technical Indicators

Indicator Ratings

Balanced or Uncertain

C4 Therapeutics (CCCC) Technical Analysis

Keep an eye on C4 Therapeutics

Frequently Asked Questions

What are the technical signals for C4 Therapeutics (CCCC) stock based on the last 30 days?

Take Your Investments to a Whole New Level